Two rooms. In one, a surgeon removes a skin cancer millimeter by millimeter and then rebuilds the face around the hole. In the other, someone is deciding whether a device is a sensible idea for a patient who came in about texture. Michelle Henry works in both.
That is not a biographical curiosity. It is the reason her career is worth reading closely in a category where inclusive aesthetics is easy to put in a press release and considerably harder to practice. A diverse gallery on a website establishes nothing about whether a clinic understands pigment biology, scarring risk, or how outcomes vary across skin tones. In medical aesthetics, inclusion has a technical component, and it lives in diagnosis and device choice, not in photography.
Controlled injury runs straight into pigment biology
Many aesthetic treatments work through controlled injury, heat or inflammation — mechanisms that interact with pigment biology in ways that matter clinically. Post-inflammatory hyperpigmentation, hypopigmentation and prolonged visible inflammation do not belong tucked into the fine print of a consent form after the device has already been chosen. They belong earlier, in the choosing.
Which is why safe for all skin tones should trigger more questions, not fewer. A broad inclusivity claim was never a substitute for naming the device and the operator’s actual experience with skin like yours.
Hair and scalp widen what aesthetic dermatology even covers
Henry’s practice includes hair-loss evaluation and restoration, which sits at the intersection of several systems at once: dermatologic disease, hormones, traction, scarring, medication, styling habits, and plain cosmetic preference, all tangled together.
Aesthetic marketing likes to jump straight to platelet-rich plasma or transplantation. A medical dermatology approach asks first what kind of hair loss is present, and whether the follicle or the underlying health context changes the plan. The principle runs through every other corner of aesthetics: the treatment name should never arrive before the problem has been identified.
Where the surgical training comes from
Henry completed dermatology residency at Mount Sinai Hospital, serving as chief resident, then pursued fellowship training in cutaneous oncology, Mohs micrographic surgery and reconstructive surgery through Harvard Medical School. She is board-certified, a Clinical Instructor at Weill Cornell, and founder of Skin & Aesthetic Surgery of Manhattan.
The surgical background matters in an aesthetics conversation precisely because skin was never only a cosmetic surface. Dermatologists also diagnose disease, treat skin cancer, and manage wounds with consequences that run well past appearance. Reconstructive dermatologic surgery is not the same practice as elective facial aesthetics, but the two share useful habits: respect for anatomy, tissue behavior, wound healing, and long-term appearance over the immediate result.
A clinician moving between those domains operates with a wider definition of a good result than a photograph taken immediately after treatment can capture. Cosmetic care is still care. The best outcome was never the largest visible change — it is the right change for the anatomy, the goals, and the maintenance someone is actually willing to own.
Inclusive marketing and inclusive evidence are not the same claim
A campaign can feature a wide range of skin tones while the underlying evidence stays narrow. That is not proof a treatment is unsafe outside the study population. It is a real limit on how confidently the result generalizes.
When a clinic claims broad suitability, ask what is behind it: were diverse skin tones tested, were pigment changes reported by subgroup, does the provider have procedure-specific experience across the relevant range. The absence of those answers does not condemn a treatment. It changes how much uncertainty you are signing up for, which is a thing worth knowing before rather than after.
Research and teaching, in a field where launches outrun the data
Henry founded The Henry Research Group and teaches at Weill Cornell. That matters because product launches routinely move faster than the comparative evidence behind them. A technically impressive platform can have a legitimate mechanism and still lack strong data for the exact use being advertised, and a treatment can perform differently across populations that were thin or absent in the original trials.
Nobody needs to become a clinical researcher over this. They do need to ask whether evidence exists for the exact device, the exact indication, and people reasonably similar to themselves.
The clearest signal is what a provider declines
The marker of real expertise is not the ability to perform a long list of procedures. It is the willingness to explain when the requested one is not the right answer. A pigment concern might need inflammation controlled first. Hair loss might need a diagnosis before a restoration package. A device that is excellent in one skin context can be unnecessarily risky in another.
A menu tells you what can be sold. Expertise tells you which option belongs to the person sitting in the room.
One limit on this file, stated plainly: both sources below are Henry’s own practice site. Everything here comes from her own materials, which is ordinary for a private practice and still means nothing here has been independently established. What her career makes visible is that inclusive aesthetics was never a softer marketing voice — it is better technical judgment, and whether a provider will change the plan when the person in front of them does not match the brochure.
The file
- Skin & Aesthetic Surgery of Manhattan: current professional biography, residency, fellowship, teaching, and clinical focus
- Skin & Aesthetic Surgery of Manhattan: practice scope and current provider information
Editorial note: This profile is based on public professional and practice information checked August 8, 2026. It is not medical advice, a personal endorsement, or a claim of treatment experience.
Source file